超出第一个进展后的阿帕蒂尼布与晚期乳腺癌患者的整体存活时间延长有关:来自观察性研究的结果
相关实验视频
Updated: Jun 29, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Jing Wang1,2,3, Jinghao Jia2, Jingjing Liu3
1Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
在疾病进展后继续服用低剂量的阿帕蒂尼布可以改善晚期乳腺癌患者的存活率. 中性粒细胞与淋巴细胞的比率 (NLR) 是治疗疗效的关键预后标志物.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期乳腺癌 (ABC) 存在重大治疗挑战.
- 确定有效的治疗策略和预后标记对于改善患者的治疗结果至关重要.
研究的目的:
- 评估低剂量阿帕蒂尼布在晚期乳腺癌中的实际有效性和安全性.
- 为了确定持续阿帕蒂尼布超过进展后的影响.
- 为了确定与治疗疗效相关的因素.
主要方法:
- 对63名接受阿帕蒂尼布 (250毫克/天) 治疗的晚期乳腺癌患者的回顾性分析.
- 患者被分为持续抗血管新生治疗超过第一次进展 (CABF) 和非CABF组.
- 评估了整体生存率 (OS),客观反应率 (ORR) 和预后因素.
主要成果:
- 客观的响应率为33.3%.
- 平均整体存活时间为16个月.
- 持续使用阿帕蒂尼布超出进展 (CABF) 和较低的中性粒细胞与淋巴细胞比率 (NLR) 与明显更长的生存期有关.
结论:
- 低剂量阿帕蒂尼布在现实世界中对晚期乳腺癌有效且安全.
- 在进展后继续服用阿帕蒂尼布可能会改善存活率.
- 对于接受阿帕蒂尼布治疗的晚期乳腺癌患者来说,NLR是一种有价值和可访问的预后标志物.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...